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“Intensive surveillance has improved the ability to detect small-volume tumor recurrence 
with a sensitivity that surpasses current understanding of the clinical implications of 
detecting clinically occult residual or recurrent disease.” 
 
 Nathan Johnson and Mitchell Tublin referring to differentiated thyroid cancer 
 
 
 
“The combination of data, statistical methodology and motivation seems a potent 
anesthetic for skepticism.” 
 
    Sander Greenland referring to treatment recommendations based 
         on epidemiological studies 
 
 
“It has been hypothesized that increased detection of low-risk disease can lead to 
overestimation of treatment efficacy and a subsequent increase in use of therapy.” 
 
Megan Haymart referring to thyroid cancer treatment  
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Introduction
Last year I won the Maurice Raben Summer Fellowship Award from the 
Endocrine Society to do research in thyroid cancer. Thyroid cancer, the most common 
and prevalent of all endocrine malignancies, accounts for more than 95% of endocrine-
related cancers.  An estimated 56,000 people will be diagnosed with thyroid cancer this 
year.1 With an annual increased incidence of about 5.5% and 6.6% in men and women 
respectively, it is, and for the last three decades has been, the fastest growing cancer in 
the United States.2 Between 1979 and 2009, for example, age-adjusted incidence per 
100,000 has increased from 4.48 to 14.25.3 There is significant geographical variation in 
reported incidence in other countries, although some differences also are presumably due 
to differences in the scope and accuracy of other countries’ reporting systems. In most 
countries, annual age-adjusted incidence per 100,000 persons has varied between 0.9 to 
2.6 in men and 2.0 to 5.9 in women over the past several decades with additional 
variation based on race, ethnicity and age.4 
 Differentiated thyroid cancer (DTC), consisting of papillary and follicular thyroid 
cancer, constitutes approximately 90% of all thyroid malignancies.5 The increase in cases 
is almost entirely attributable to an increase in papillary thyroid cancer (PTC). The total                                                         
1 "Thyroid Cancer Treatment (PDQ®)" National Cancer Institute, 
http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page1#Reference1.1 
(accessed 4/20/2012). 
2 American Cancer Society, Cancer Facts & Figures 2012 (Atlanta: Georgia, 2012), 
http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012 
(accessed 4/21/2012).  
3 National Cancer Institute, "Cancer of the Thyroid - SEER Stat Fact Sheets" 
http://seer.cancer.gov/statfacts/html/thyro.html (accessed 4/21/2012). 
4 Gorges, R., “The Changing Epidemiology of Thyroid Cancer” in Thyroid Cancer: Current Concepts in 
Diagnosis and Therapy, eds. Biersack, H.J. and Grunwald, F. (Berlin Springer-Verlag 2d ed. 2005) 6. 
5 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated 
Thyroid Cancer and others, "Revised American Thyroid Association Management Guidelines for Patients 
with Thyroid Nodules and Differentiated Thyroid Cancer" Thyroid (2009) 19:1167-1214. 
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number of PTC cases in the United States increased by more than 300% from 1973-74 to 
2003-04.6 A significant portion of the PTC cases in turn consists of papillary thyroid 
microcarcinomas (PTMC) measuring 1 cm or smaller which for example, increased by 
441% between 1983 and 2006.7 There is no generally accepted explanation for these 
startling rates of increase. 
The number of persons diagnosed with thyroid cancer is expected to continue to 
increase. It is estimated that approximately 13-67% of people will have thyroid nodules 
during their life of which approximately 5% will be malignant regardless of size.8  The 
standard treatment, a thyroidectomy frequently followed by radioactive 131 iodine 
treatment and a lifetime of thyroid replacement therapy, accordingly would seem to be a 
likely future event for an increasing percentage of the population.  
Despite the magnitude of the increase, there has been minimal or no increase in 
age-adjusted mortality rates depending on the particular time periods selected. In the 
United States, age-adjusted mortality for all ages, both sexes, in 1979 was 0.5276 as 
compared to 0.5213 in 2009.9 Between 1975 and 1988, there was a negative 2.2 annual 
percentage change and between 1988 and 2009, a positive .8 annual percentage change in 
age-adjusted mortality in the United States.10 It is estimated that approximately 1780 
people in the United States will die from thyroid cancer this year. Although the majority 
of these cases involve DTC, simply because they are the overwhelming percentage of 
cases, it also includes many who were diagnosed with the other more rare and serious                                                         
6 Guo-Pei Yu, James Chun-Lun, et al. "Thyroid Cancer Incidence and Survival in the National Cancer 
Institute SEER Race Ethnicity Groups" Thyroid  (2010) 20:468.  7 Yu, Xiao-Min, Yin Wan, Rebecca Sippel and Herbert Chen, “Should All Papillary Thyroid 
Microcarcinomas be Aggressively Treated?” Annals of Surg (2011) 254:653.  
8  M. J. Yeung and J. W. Serpell, "Management of the Solitary Thyroid Nodule" Oncologist  (2008) 13:105. 
9  National Cancer Institute, Cancer of the Thyroid - SEER Stat Fact Sheets  
10  National Cancer Institute, Cancer of the Thyroid - SEER Stat Fact Sheets  
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forms of thyroid cancer.11 Survival rates for younger patients (< age 40-45) after a 
thyroidectomy for PTC, the most common form of DTC, are variously reported as 95-
99%.12  Thyroid cancer is a benign diagnosis for most, but not all, DTC patients.   
 Women have a significantly higher incidence of thyroid cancer than men and 
account for a larger percentage of the increased incidence. Thyroid cancer ranks as one of 
the top 6 types of cancer in women, but does not enter the top 15 in men.13 However, in 
males it presents in more aggressive and lethal forms. This epidemiological peculiarity, 
though baffling, may yield some of the most potent and exciting clues into how sex-
specific hormones such as estrogen affect not only the growth of thyroid cancer but also 
all cancers. Population disparities in incidence and outcome have been responsible for 
significant medical revolutions. It is possible that progress in understanding this cancer 
will provide a new understanding of human physiology.   There is no generally accepted explanation for the sexual disparity. The female-
to-male ratio in DTC is about 3:1 with significant variation at different ages. At puberty 
the female-to-male ratio may be as high as 14:1 with declining ratios as age increases.14 
Interestingly, in children under age ten there is no difference in incidence between girls 
and boys and the higher female incidence decreases after menopause.15 There also is no 
sex difference in incidence in clinically irrelevant papillary microcarcinoma <1 cm found                                                         
11  Thyroid Cancer Treatment (PDQ®)  
12  Rebecca L. Brown, "Thyroid Cancer: Burden of Illness and Management of Disease" Cancer (2011) 
2:194. 
13  L. Enewold et al., "Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor 
Characteristics, 1980-2005" Cancer Epidemiology, Biomarkers & Prevention (2009) 18:784-791.  14 Farahati, J., P. Bucsky, T. Parlowsky, U. Mader, and C. Reiners. "Characteristics of Differentiated 
Thyroid Carcinoma in Children and Adolescents with Respect to Age, Gender, and Histology," Cancer 
(1997) 80:2156-2162. 
15  D. M. Morris et al., "Localized Well-Differentiated Thyroid Carcinoma: Survival Analysis of Prognostic 
Factors and (131)I Therapy" Annals of Surgical Oncology (1998) 5:329-337.; L. E. Sanders and B. Cady, 
"Differentiated Thyroid Cancer: Reexamination of Risk Groups and Outcome of Treatment" Archives of 
Surgery (1998) 133:419-425.  
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in autopsy studies of persons who died from causes unrelated to thyroid disease, which 
presumably means that some sex-linked factor causes the microcarcinoma to be more 
likely to become clinically relevant in females.16 In fact, estrogen receptor (ER) action 
has been shown to regulate cell growth and apoptosis by participating in mitochondrial 
homeostasis in papillary thyroid cancer cell lines.17 
My research was directed at cellular function that may help to explain the higher 
rate of female incidence. Communication between the cell nucleus and the mitochondria 
(retrograde signaling) is believed to control estrogen-induced signaling involved in the 
apoptosis, proliferation, and differentiation of both normal and malignant cells.18 In 
thyroid cancer cells, E2 mediated extracellular signaling may regulate tumor cell growth 
and apoptosis.19 Rapidly dividing cancer cells are known to produce significant amounts 
of intracellular reactive oxygen species (ROS), which appears to promote accelerated cell 
cycle activity in neoplastic cells.20 As the largest producer of ROS, mitochondria may 
participate in the development and progression of cancers. ROS (mitochondrial and 
extramitochondrial derived) are implicated in the regulation of signal transduction 
pathways leading to control of gene expression and post-translational modification of 
proteins.21 Therefore, understanding ROS-induced mitochondrial signaling and                                                         16 Drucker, William D. and Richard J. Robbins, “Papillary Microcarcinoma of the Thyroid,” in Practical 
Management of Thyroid Cancer: A Multidisciplinary Approach eds. Mazzaferri, Ernest L., et al. (London 
Springer-Verlag 2006) 371-73. 
17  Q. Zeng et al, "The Contributions of Oestrogen Receptor Isoforms to the Development of Papillary and 
Anaplastic Thyroid Carcinomas" Pathology (2008) 214:429-432; Q. Felty and D. Roy, "Estrogen, 
Mitochondria, and Growth of Cancer and Non-Cancer Cells" Carcinogenesis (2005) 4:1. 
18 Ibid. 
19 Zeng et al., “The Contributions of Oestrogen Receptor Isoforms to the Development of Papillary and 
Anaplastic Thyroid Carcinomas” Pathology 214:429-433. 
20 Felty and Roy, “Estrogen, Mitochondria, and Growth of Cancer and Non-Cancer Cells,” Carcinogenesis,  
(2005) 4:1. 
21 R. G. Allen and M. Tresini, "Oxidative Stress and Gene Regulation" Free Radical Biology & Medicine 
(2000) 28:463-499; C. K. Sen, "Antioxidant and Redox Regulation of Cellular Signaling: Introduction" 
Medicine and Science in Sports and Exercise (2001) 33:368-370. 
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mitochondrial regulation of ER expression may provide new insight into thyroid cancer 
progression and metastasis. 
Thyroid cancer cell research is complicated by the recent discovery that a 
substantial amount of research has been conducted with contaminated or redundant cell 
lines. One recent study found that up to 36% of the thyroid cancer cells being used for 
research were misidentified as thyroid cancer cells or were contaminated by other cancer 
cells. Another major study found only 20 of 40 common cell lines to be correctly 
identified.22 The degree to which this misidentification has distorted reported research 
results is unknown. 
My research was conducted under the direction of (the truly wonderful) Dr. 
Sharon Elliot at the University of Miami Miller School of Medicine Department of 
Surgery Endocrinology Lab. I spent my winter break period in the lab conducting an 
extensive review of the literature, learning the methods and techniques that I would need 
over the summer and gaining an introduction to the lab.   
We set up an experiment to derive and propagate thyroid cancer cell lines from 
fresh surgical specimens and then remove the nucleus from the cancer cells with 
actinomycin D under conditions that preclude recovery of treated cells. The next step was 
to remove mitochondrial DNA from control cells using a two-week treatment with 
ethylene bromide. This would allow us to fuse the cells using 45% polyethylene glycol 
(12). The intention was to create cells that contained mitochondrial DNA (mtDNA) of 
cancer cells and a nucleus from control cells. Prior to the development of the cybrids, the 
mtDNA of each cell line would be sequenced to determine the unique polymorphisms                                                         
22  R. E. Schweppe et al., "Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell 
Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification" Clinical 
Endocrinology & Metabolism (2008) 93:4331. 
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present in the mtDNA. This fingerprint could be used to ensure that the cybrids contain 
only the mtDNA from the cancer cells. Respiration and ROS content can then be 
determined before and after cybrid production. ER expression can be determined by real 
time PCR and western analysis and invasion assays. This research with some variation is 
now ongoing with results that are not ready for publication. 
 Obtaining genuine cancerous thyroid cell lines obviously is critical for all thyroid 
cancer research. Dr. Elliot’s laboratory at the University of Miami is particularly well 
situated to address this issue because of its proximity to the surgical suites where the 
patients’ thyroids are removed. Dr. Elliot’s lab harvests the cell lines directly from the 
thyroid cancer patients at Jackson Memorial, the University of Miami’s teaching hospital. 
Dr. John Lew, an endocrine oncology surgeon at the University of Miami Medical School 
and one of Dr. Elliot’s colleagues, also invited me to shadow thyroid surgeries in order to 
learn more about biopsies and creation of cell lines.  
My interest in the thyroid is personal. I began having unexplained symptoms 
when I was a teenager. An eventual diagnosis of hypothyroidism, perhaps caused by a 
virus, was made only after considerable delay. I was an athlete engaged in intensive 
physical training and exhaustion resulting from pathology was not the most obvious 
diagnosis. It was striking, however, how vague the guidelines were on symptoms, blood 
tests and monitoring the inception, continuation and diminution of treatment. Also 
striking has been how many other people I meet on a daily basis who also suffer from 
thyroid conditions. 
Until recently, most of the medical community attributed the increased incidence 
in thyroid cancer to increased diagnostic capabilities resulting from advances in 
7  
technology rather than an actual increase in prevalence based on data showing that 87% 
of the increase was attributable to tumors measuring less than 2 cm., the absence of any 
significant improvement in therapy which might explain the unchanged mortality rates 
and the absence of any clear evidence of a risk factor responsible for the increased 
incidence.23 Recent evidence suggests that this reasoning is not fully accurate.24 A 
subsequent comprehensive study of this issue, which examined 48,403 thyroid cancer 
patient records, concluded that at least 50% of the increase could not be explained solely 
by increased diagnostic capabilities.25 Most endocrinologists now acknowledge that more 
research needs to be done for a more complete understanding of the increase.26   
Improved ultrasound and fine needle biopsy technology enables doctors to more 
easily find smaller tumors that older technology would overlook in all types of cancer. 
However, studies show an increase in thyroid tumors of all sizes and types across all 
communities. This contradicts the belief that the increase is solely the result of smaller 
tumors now being detected with better technology but leaves open the determination of 
precisely how much of the increased incidence is clinically significant.27 The next phase 
of research now is beginning to focus on other factors such as environmental, dietary, and 
                                                        
23 Davies, Louise and H. G. Welch, "Increasing Incidence of Thyroid Cancer in the United States, 1973-
2002” JAMA (2006) 295:2164-2167. 
24 Enewold et al., “Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor 
Characteristics, 1980-2005” Epidemiology, Biomarkers and Prevention (2009) 18:784-791; Yu, Guo-Pei, et 
al. "Thyroid Cancer Incidence and Survival in the National Cancer Institute SEER Race Ethnicity Groups" 
Thyroid (2010) 20:470-473; Amy Y. Chen, Ahmedin Jemal and Elizabeth M. Ward, "Increasing Incidence 
of Differentiated Thyroid Cancer in the United States, 1988-2005" Cancer (2009) 115:3807. 
25  Enewold et al., “Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor 
Characteristics, 1980-2005” Epidemiology, Biomarkers and Prevention (2009) 18:784-91.   
26 Shari Rudavsky, "Medical Researchers Unsure Why Thyroid Cancer Cases on the Rise – 
USATODAY.com " http://www.usatoday.com/news/health/story/health/story/2012-01-15/Doctors-unsure-
why-thyroid-cancer-cases-on-the-rise/52582694/1 (accessed 4/20/2012).. 
27 Chen, Jemal and Ward, “Increasing Incidence of Differentiated Thyroid Cancer in the United States, 
1988-2005” Cancer (2009) 115:3807. 
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genetic causes that may explain some portion of the increasing incidence in thyroid 
cancer.    
  Despite the pressing issues raised by its growth rate, thyroid cancer is one of the 
least studied and least funded cancers in the United States.28 Although there is almost no 
reliable data on its economic impact, its prevalence makes it likely that it is becoming one 
of the more expensive diseases in our health care system. There remains much to be 
questioned, much less understood, in the realm of thyroid cancer. This thesis is a 
presentation of what is known, about thyroid cancer with the intent of fostering more 
research, awareness, and education on the subject.  
                                                        
28 "Cancer Research Funding," National Cancer Institute, 
http://www.cancer.gov/cancertopics/factsheet/NCI/research-funding (accessed 4/18/2012). 
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Chapter 1: The Facts: An Introduction to the Thyroid and Thyroid Cancer 
The thyroid is tucked away inside the lower part of the neck wrapped around the 
trachea. It is a butterfly-shaped organ with two lobes connected by a narrow bridge called 
the isthmus.  It weighs about 20 grams and is approximately the size of a quarter. Three 
main arteries, the superior thyroid 
artery, inferior thyroid artery, and the 
thyroideaima, supply about 5 mL of 
blood per gram of tissue to the thyroid, 
twice as much as what is supplied to 
each kidney.  
Thyroid function is essential  
for every cell in the human body. It is 
responsible for regulating appropriate amounts of the pituitary gland’s secretion of 
thyrotrophin (known as Thyroid Stimulating Hormone or TSH) to carry out bodily 
functions including the synthesis and storage of hormones that regulate metabolism, heart 
rate, body temperature, and tissue growth. The thyroid secretes three hormones, 
triiodothyronine (or T3, indicating 3 iodine atoms), thyroxine or tetraiodothyronine (or 
T4, indicating 4 iodine atoms), and calcitonin (CT). The synthesis of T3 and T4 are 
dependent on dietary iodine and are regulated by TSH. The hormones are controlled via 
thyrotrophin releasing hormone (TRH) from a negative feedback pathway beginning in 
the anterior pituitary gland whose thyrotroph cells produce TSH. The precise roles of T3 
and T4 once released into the bloodstream by the thyroid are poorly understood.  
Figure 1: The Thyroid. Image adapted from:  
The Mayo Clinic. "Thyroid Cancer." 
http://www.mayoclinic.com/health/thyroid-
cancer/DS00492 (accessed 4/02/2012). 
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Thyroid dysfunction is implicated in a number of diseases including, but not 
limited to, hyperthyroidism, hypothyroidism, Grave’s disease, Hashimoto’s thyroiditis, 
and goiter. There is a rich history of thyroid disease in medicine. There are reports as 
early as 2700 B.C. of the treatment of enlarged thyroids 
using burnt seaweed and sponges in Chinese medicine 
whose efficacy was due to the iodine contained within. In 
961, Abul Kasim, a court physician in Codoba, described 
the first thyroidectomy and thyroid biopsy for goiter. 
Thomas Wharton, who drew the original surgical 
sketches of thyroidectomy procedures, named the thyroid 
in 1656 after the Greek word for shield “thyreos,” based 
on the shape of the near-by thyroid cartilage.29 In 1909,  
Theodor Kocher won the Nobel Prize in Medicine for his      
research on the thyroid and complications following 
thyroidectomies. His work resulted in a reduction in 
thyroidectomy mortality from 14% in 1884 to .18% in 
1898.30  
The discovery of the role of iodine in goiter was the first recognized discovery of 
the association between the environment and human health and the first discovery of the 
importance of a trace element to human health. It is one of the most significant public 
                                                        
29 Sawin, Clark T., “The Heritage of the Thyroid,” in Werner & Ingbar’s The Thyroid: A Fundamental and 
Clinical Text (8th ed.), ed. Lewis E. Braverman and Robert D. Utiger (Philadelphia: Lippincott Williams & 
Wilkins 2000) 3. 
30  Ibid; "American Thyroid Association Thyroid Timeline" American Thyroid Association, 
http://www.thyroid.org/professionals/education/timeline.html (accessed 4/18/2012). 
Figure 1: “La Resurrezione” 
(Figure 1A) and “La Madonna del 
Parto” by Piero Della Francesca. 
Each painting identifies goiter from 
iodine deficiency in Borgo San 
Sepolcro, the village where Della 
Francesca was born. Image adapted 
from International Council for the 
Control of Iodine Deficiency 
Disorders. "IDD Newsletter" no. 39 
(Feb 2011): 1-20 
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health discoveries of modern epidemiology.31 Health problems resulting from iodine 
deficiency, collectively referred to as iodine deficiency disorders, or IDDs, can cause 
mental retardation, growth and development impairment in children including hearing 
and speech impediments, and miscarriages, still births, and other complications in 
pregnant women. Congenital hypothyroidism resulting from iodine deficiency 
(hypothyroidism at birth) is the single most common cause for preventable mental 
retardation and even mild deficiencies may be associated with low intelligence in 
children.32  
Approximately 2.2 billion people (38%) in the world live in iodine-deficient 
areas.33 According to the International Council for the Control of Iodine Deficiency 
Disorders (ICCIDD), “iodine deficiency was once considered a minor problem, causing 
goiter [sic], an unsightly but seemingly benign cosmetic blemish. However, it is now 
known that the effects on the developing brain are much more deadly, and constitute a 
threat to the social and economic development of many countries.”34  Only small 
amounts (100–150 μg) of iodine are required daily to prevent any complications, making 
iodine deficiency disorders one of the most easily preventable illnesses in public health.35  
                                                        
31  C. C. Johnson, F. M. Fordyce and A. G. Stewart, Environmental Controls in Iodine Deficiency 
Disorders- Project Summary Report (Nottingham, UK: British Geological Survey, 2003) (accessed 
4/18/2012).  
32 "Thyroid.Org: Iodine Deficiency" 
http://www.thyroid.org/patients/patient_brochures/iodine_deficiency.html (accessed 4/9/2012); 
International Council for the Control of Iodine Deficiency Disorders, "IDD Newsletter" 39, Feb 2011 
(2011): 1-20 (accessed 4/21/2012). 
33  Johnson, Fordyce and Stewart, Environmental Controls in Iodine Deficiency Disorders- Project 
Summary Report, 2.  
34  Ibid.  
35  Ibid. 
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Thyroid conditions are collectively referred to as thyroid disease.  It is estimated 
that about 1 in 10 Americans suffer from abnormal TSH levels.36  The most common 
functional disorder is hypothyroidism which results from the production of insufficient 
amounts of thyroid hormones. Prevalence of overt hypothyroidism is estimated to be 
approximately 1-2% in women and 0.1% in men. Subclinical hypothyroidism (elevated 
TSH but otherwise normal T4 values), which progress to overt hypothyroidism in 5-18% 
of patients per year, occurs in 4-10% of the United States population.37 Women have a 
significantly higher prevalence of thyroid disease than men.38 This is important because, 
after radiation, the most significant risk factor for thyroid cancer is benign thyroid disease 
and goiter.39   
Thyroid disease, including thyroid cancer, leads to a remarkable number of 
thyroidectomies. A recent study surveyed the largest database of hospital admissions and 
found that 59,478 patients (74.8% female, 30.8% malignant neoplasm) were admitted and 
underwent thyroidectomies in 2009. The authors noted that it is believed that nearly 50% 
of thyroidectomies are performed on an out-patient basis and thus are not included in 
those statistics.40 It is likely that these numbers have increased since 2009. 
                                                        36 Carnaris GJ, Manowitz NR, Mayor G Ridgway EC. “The Colorado Thyroid Disease Prevalence Study” 
Arch Intern Med (2000) 160:526-534. 37 McDermott, Michael T. and E. Chester Ridgway, “Diagnosis and Treatment of Hypothyroidism,” in 
Medical Management of Thyroid Disease. David S. Cooper ed. (New York Marcel Dekker, Inc. 2001) 136.  38 Wang, Clifford and Lawrence M. Crapo, “The Epidemiology of Thyroid Disease and Implications for 
Screening” Epidemiology and Clinical decision Making (1997) 26:189-218. 39 Gorges, R., “The Changing Epidemiology of Thyroid Cancer” in Thyroid Cancer: Current Concepts in 
Diagnosis and Therapy, Biersack, H.J. and Grunwald, F. (eds). (Berlin Springer-Verlag (2d ed.) (2005) 20; 
Figge, James J., “Epidemiology of Thyroid Cancer” in L. Wartofsky and Douglas Van Nostrand, Thyroid 
Cancer: A Comprehensive Guide to Clinical Management, 9. 
40 Vashishta, Rishi, et al., “Thyroidectomy Outcomes: A National Perspective” Otol. Head Neck Surgery 
July 2012. 
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Thyroid disease, as well as thyroid cancer, is inexplicably increasing annually 
resulting in depression, exhaustion, and temperature, metabolic, and appetite 
irregularities among an estimated 70 million Americans. Like thyroid cancer, it now is 
believed that the increase in thyroid disease is attributed to more than just increased 
diagnosis and detection of preexisting pathology.  The mystery behind the increase of 
thyroid conditions has become one of the confounding current medical puzzles.   
Despite its enormous importance and long history, relatively little is known about 
the thyroid and its physiology. There is continuing controversy over the reference range 
for “normal” TSH serum levels. Although the results differ among groups of patients, 
many tests of thyroid function have little diagnostic value because there is too much 
overlap between individual patients.41 In sample populations, iodine deficiencies are 
diagnosed based on the median urinary iodine concentration (UIC), the amount of iodine 
excreted in urine. A diagnosis of iodine sufficiency in a population, because it is based on 
median measurements, does not determine whether there is a subgroup who suffers from 
a deficiency or the size of the subgroup and the degree of their deficiency. The 
populations used are normally school-age children because of the relative simplicity of 
obtaining their urine samples and there is limited data on high-risk groups such as 
pregnant women and women generally.42 Similarly, hypothyroidism, the condition 
resulting from an underactive thyroid that produces insufficient thyroid hormones, does 
not have characteristic symptoms. There are no symptoms always present and many 
                                                        
41 Smallridge, Robert C., “Metabolic, Physiologic and Clinical Indexes of Thyroid Function,” in Werner & 
Ingbar’s The Thyroid: A Fundamental and Clinical Text (8th ed.), ed. Lewis E. Braverman and Robert D. 
Utiger (Philadelphia: Lippincott Williams & Wilkins 2000) 393, 398. 
42  International Council for the Control of Iodine Deficiency Disorders, IDD Newsletter  (Feb.  2012) 40:1 
(accessed 4/21/2012). 
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symptoms are common to other disease. The resulting lack of understanding and clarity 
complicates any analysis of thyroid issues in public health. 
Thyroid Cancer  
For how little is known about the thyroid, even less is known about thyroid cancer. 
It is the most common and prevalent of all endocrine malignancies and accounts for more 
than 95% of endocrine-related cancers. There are four types of thyroid cancer which are 
grouped based on their cell morphology (referred to as histology) as follows: papillary, 
follicular, medullary, and anaplastic. Hurthle cell cancer, a form of follicular cancer, is 
frequently listed as a fifth type because it has a distinctive appearance and is less 
responsive to standard therapy.43  
Research in cellular function in thyroid cancer is therefore critical for 
understanding the mechanism and providing new drugs and therapy options. It not only 
assists cancer research but it has also helped developed drugs for other illnesses. As it 
turns out, however, much of our understanding of thyroid biology has been confounded 
by misinformation. Many of the cells that have been used in the last 25 years in thyroid 
cancer research have been shown to be either redundant or from another organ besides 
the thyroid. Recent studies suggest that up to 36% of cells being used for thyroid cancer 
research fall under this category. One of the most comprehensive studies analyzing 40 
thyroid cell lines found only 50% accuracy in identification, 20 of the cell lines were 
                                                        
43  Brown et al., "Thyroid Cancer: Burden of Illness and Management of Disease" Cancer (2011) 2: 193. 
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either redundant or misidentified.  One cell line, A-375, was found to originate from 
melanoma. The cell line has been used since 1973 on multiple studies in thyroid cancer.44 
Papillary cell carcinoma, is by far the most prevalent, and most treatable, of the 
thyroid cancers, comprising about 80% of diagnosed cases each year and cure rates 
approaching 97-99% for younger patients (< age 40-45).45 It is found primarily in 
females younger than 45. Follicular thyroid cancer comprises about 15% of thyroid 
cancer cases and is the most difficult to diagnose. Together papillary and follicular 
carcinomas are referred to as well-differentiated or differentiated thyroid cancer (DTC), 
meaning that they physically resemble normal thyroid cells. They grow slowly and are 
generally non-lethal even in cases of relapse. While advanced papillary metastases center 
around the neck, follicular cancer can spread further afield into the body such as the lungs 
and brain. Cure rates for follicular cancer can vary from 40-99% depending on whether it 
has become metastatic.46 
There are other variants in DTC. It is common for follicular cancer cells to be 
intermixed with papillary cancer cells which does not seem to alter prognosis. Other less 
common variants include “tall,” “columnar” and “insular” cells which are believed to be 
more aggressive with a poorer prognosis. These variants include between 3-16% of 
papillary cancer cells with columnar at 1-7% which is particularly confounding for 
statistical analysis because it seems to be the only form of PTC that is more prevalent in 
                                                        44  R. E. Schweppe et al., "Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell 
Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification" Clinical 
Endocrinology & Metabolism (2008) 93:4331. 
45 Wartofsky, Leonard, “Staging of Thyroid Cancer” in, Thyroid Cancer: A Comprehensive Guide to 
Clinical Management, ed. L. Wartofsky and Douglas Van Nostrand (New York Springer 2005) 87.  
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men.47 The staging systems to predict risk, however, include all of these potentially 
distinctive cancers within the general papillary staging profile.48  Similarly, there is a 
growing amount of literature identifying common tumor genes with increasing evidence 
of predictive value for more aggressive tumors that are not differentiated by staging 
systems.49 
 Medullary thyroid cancer comprises about 5% of thyroid cancer cases. It occurs 
in "C" cells, or parafollicular cells, which are neuroendocrine cells that regulate calcium 
levels in the body.  They are not classified according to differentiation (or appearance) 
because they are not thyroid cells. Instead they are categorized by origin as either 
sporadic (non-hereditary), multiple endocrine neoplasia (MEN) 2A or 2B associated (a 
genetic disease associated with hormone gland tumors), or familial (inherited). The 10-
year survival rate is variously reported at 50-80%, representing about 13% of thyroid 
cancer mortality.50 
Anaplastic thyroid cancer (also called undifferentiated for its stark contrast to 
normal thyroid cells) is the most rare and deadly form of thyroid cancer. It accounts for 
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only about 2% of thyroid cases but 14-50% of mortality from thyroid cancer.51  
Interestingly, most patients are 65 or older when they are diagnosed.  Because of its fast 
rate of growth and location in the neck, it constricts airflow and causes difficulty 
breathing. Patients generally live less than 3-5 months after diagnosis. Some percentage 
of anaplastic thyroid cancer is the result of slow transformation of DTC tumors. This 
possibility has been cited as a reason for aggressive treatment of DTC.52 The introduction 
of dietary iodine is believed to reduce anaplastic cancer and, unlike other thyroid cancers, 
anaplastic thyroid cancer incidence is decreasing worldwide.53 
The majority of DTC patients show no symptoms, although some people show a 
lump or swelling in the neck originating in the lymph nodes or complain of trouble 
breathing or swallowing. It is common for doctors to attribute these symptoms to causes 
other than cancer before making the thyroid cancer diagnosis. The first indication of 
thyroid cancer is a nodule, or a tumor, growing in the thyroid tissue. In some cases 
pressing or palpating around the neck will reveal a nodule. Doctors will visualize nodules 
using a CT scan, MRI, radioactive iodine scan, or, most frequently, an ultrasound exam. 
Most cases of thyroid cancer in the United States are found during non-related diagnostic 
procedures or after the disease has considerably progressed.54 A common example of this 
is visualization of nodules during a CT or MRI for spinal cord injuries following a car 
accident. Finally, a fine-needle aspiration biopsy  (FNAB) or surgical biopsy of the 
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thyroid is performed and cells are collected to determine if the tumor is benign.55 In the 
case of familial forms of medullary thyroid cancer, a simple DNA blood test for the RET 
gene can be used for diagnosis.  
        Once diagnosed, doctors determine the staging, or the extent to which the cancer 
has progressed, to decide treatment protocol. Staging is also used to determine prognosis. 
Disease classified as stage 1 or 2 are “low risk” while stage 3 or 4 are “high risk,” with a 
higher chance of residual disease after treatment, recurrence or death. The overwhelming 
number of patients are diagnosed with stage 1 or 2 thyroid cancer because of the low rate 
of mortality. Most papillary thyroid cancer patients, for example, will have a 25-year 
survival rate of about 97% after treatment.56 Despite the reassuring scientific tone of this 
summary, reality when applied to actual patients is more complex. 
Determination of staging can be elusive and unreliable. It is extremely difficult to 
determine the history of the patients’ thyroid cancer from how it presents upon diagnosis. 
Tumors can vary drastically from patient to patient, with some metastasizing regionally 
or distantly for no apparent reason.  Some people die quickly from aggressive tumors that 
in others remain dormant for years. In terms of absolute numbers, there are many more 
deaths among low-risk DTC patients than high-risk patients because there are so many 
more patients with low-risk staging given the generally benign outcomes.57 
Fundamentally, staging must be viewed as an initial evaluation with recognition that it 
does not incorporate any subsequent events to update the evaluation. 
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In thyroid cancer, staging is determined by the various known determinants of 
outcome including histologic tumor type, tumor size, growth pattern, the presence of 
metastases, patient’s history, predicted duration of cancer, age and gender. Differentiated 
thyroid cancer patients are usually categorized further into high- and low-risk groups by a 
number of scoring systems developed by a number of different clinics around the country. 
There are at least fifteen different staging systems, a number which shows that none have 
demonstrated any significant superiority.58 Some of the most commonly used ones are 
the AMES (Age, Metastases, Extent, and Size), TNM (Tumor, Node, and Metastases 
(developed by the American Joint Commission on Cancer and the American Thyroid 
Association)), the AGES (Age, Histologic Grade, Extent, Tumor Size), MACIS 
(Metastases, Age, Completeness of resection, Invasion, Size of tumor) and the Memorial 
Sloan-Kettering Cancer Center systems. The European Consensus does not use any of 
these systems and instead simply categorizes levels of risk i.e. “very low” or “high” 
through defined risk factors. The systems classify based on the primary factors of patient 
age, tumor size, and extent of the tumor with additional factors according to preference. 
For example, low-risk individuals in the AMES system show papillary or follicular 
thyroid cancer with no evidence of metastases, are less than 40 years if male or less than 
50 years if female, the tumor is smaller than 5 cm and shows no signs of extrathyroidal 
invasion (for papillary) or major vascular or capsular invasion (for follicular). Everyone 
else is considered high risk including medullary and anaplastic thyroid cancer patients.59 
A study by Sanders and Cady using 1019 patients treated between 1940 and 1990 with a                                                         
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median follow-up of 13 years to investigate the validity of the AMES criteria showed that 
high-risk individuals have a mortality rate of about 50% with a recurrence rate of 31%, 
while low-risk individuals have a mortality rate of about 4%, with a recurrence rate of 
5%.60  
There have not been any prospective, randomized treatment or prevention trials, 
to determine optimal treatment in thyroid cancer because they are inherently long and 
expensive and survival rates from total thyroidectomy are exceptional.61 Surgery is the 
uniform treatment option for thyroid cancer for differentiated thyroid cancer based solely 
on retrospective studies.62 Patients with advanced thyroid cancer will undergo a total 
thyroidectomy in which the entire thyroid is removed, followed by postoperative 131 
iodine (131I) therapy to diagnose and treat metastases and thyroid hormone suppression 
therapy.63 Most low-risk patients also will undergo a total thyroidectomy and thyroid 
hormone suppression therapy and many will also receive 131I therapy. Patients with small 
tumors sometimes undergo lobectomies, in which only one lobe or wing of the thyroid is 
removed, sometimes along with the isthmus.  
In DTC, both the extent of the surgery and, for small tumors <1cm, whether to 
perform surgery are controversial decisions that in practice seem to generally depend on 
the individual surgeon and patient.64 There has been a growing trend among surgeons to 
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advocate for total thyroidectomy. Before the 1980’s, twice as many partial 
thyroidectomies as total thyroidectomies were performed. Between 1979-2004, the trend 
reversed as surgeons performed increasing numbers of total thyroidectomies. In most 
retrospective studies, total thyroidectomy has been shown to improve disease-free 
survival and reduce recurrence rates. Some argue that total thyroidectomies are 
unnecessarily invasive for some categories of patients.65  
 In order to provide appropriate care based on current knowledge, there has been 
an attempt to standardize care to enhance the treatment of thyroid cancer. The American 
Thyroid Association (ATA) originally developed treatment guidelines in 1996. British 
Thyroid Association, Royal College of Surgeons, National Comprehensive Cancer 
Network, American Association of Clinical Endocrinologists, and the American Head 
and Neck Society have also published guidelines for clinical management of thyroid 
tumors. The ATA subsequently convened a task force of leading experts who produced 
the ATA Guidelines in 2006. The Revised American Thyroid Association Management 
Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer 
Guidelines (2009 Guidelines) were reissued in 2009 to reflect changes in medical practice 
and new evidence.66 The 2009 Guidelines have been endorsed by the Endocrine Society 
and other leading professional organizations and are the current standards.  
 Treatment guidelines, however, do not necessarily induce compliance among 
surgeons. In a study on medullary thyroid cancer treatment in 2010, Panigrahi et al.                                                                                                                                                                      
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found that practice patterns in the United States did not follow ATA guidelines.67 The 
authors found that 41% of surgical patients did not receive appropriate surgery. Surgeons 
chose to operate less aggressively on patients with known distant metastases and 
prescribe more EBRT therapy. Patient age >65 and female sex were statistically 
significant predictors of treatment in noncompliance with the guidelines. Patients 
receiving treatment that did not correlate with recommendations exhibited worse 
outcomes.  
 In another comprehensive study testing whether radioactive iodine treatment 
followed some discernable rationale, Haymart et al. found that there was an  increase in 
radioactive iodine treatment from 40 to 56% of all patients between 1990 and 2008.  
The treatment provided patients frequently was not correlated with patient and tumor 
characteristics, but instead, to a significant extent, was based on unexplained variance 
among hospitals.68 There was substantial variation in the prescribed radioactive iodine 
practice patterns among surgeons with only 21.1% of the variation correlated with patient 
and tumor characteristics. The study found that hospitals with high volumes of thyroid 
cancer prescribe higher levels of radioactive iodine and that younger age and absence of 
co-morbidity was associated with a higher probability of receiving radioactive iodine.  
Female sex, African American race, and the absence of private/government insurance 
were associated with significantly less likelihood of receiving radioactive iodine. There 
were both significant instances of overtreatment with the associated risks of serious side 
effects which include other solid malignancies, leukemia and strong correlations with                                                         67  B. Panigrahi, et al., "Medullary Thyroid Cancer: Are Practice Patterns in the United States Discordant 
from American Thyroid Association Guidelines?" Annals of Surgical Oncology (2010) 7:1490-98. 68 Haymart, M. R., M. Banerjee, A. K. Stewart, R. J. Koenig, J. D. Birkmeyer, and J. J. Griggs. "Use of 
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bone, soft tissue colorectal and salivary gland cancers and the loss of teeth and 
undertreatment which results in increased mortality and complications from unchecked 
thyroid cancer.69 
There are six major reasons why more extensive surgery has become the norm 
(and is recommended in the Guidelines).  Malignancy is found in both lobes in about 30-
85% of cases, which eliminates the option of lobectomy. About 4.7-24% of patients have 
recurrent cancer, which has higher mortality rates. A total thyroidectomy obviously 
eliminates the possibility of recurrent thyroid cancer (but not other types of recurrence) 
unless remnants were left from the surgery. (The variation in percentage is based on the 
range found in different studies and provides further evidence of the poor understanding 
of the disease process.) Most studies have shown that in tumors greater than 1.5 cm total 
thyroidectomy has better outcomes. The efficacy of 131I post-operative treatment 
improves with total thyroidectomy. Serum thyroglobulin can be used with total 
thyroidectomy to determine presence of metastases. Finally, follow-up surgery if required 
by a recurrence has an increased rate of complications.70  
Notwithstanding these apparently substantial grounds, other studies continue to 
question whether thyroidectomies are necessary for less advanced cases when a 
lobedectomy, or even observation without surgery, could be sufficient. Proponents of 
lobectomies cite that less than 5% of recurrences are found in the thyroid making 
thyroidectomies seem heavy-handed.71 There is also an increased risk of complications 
                                                        
69 Ibid.  
70 Udelsman, Lakatos and Ladenson, Optimal Surgery for Papillary Thyroid Carcinoma, World J Surg 
(1996) 20:88-93. 
71 R. L. Rossi et al., "Malignancies of the Thyroid Gland: The Lahey Clinic Experience" The Surgical 
Clinics of North America (1985) 65:211-230. 
24  
with total thyroidectomy and it does not remove lymph node metastases. More 
importantly, many tumors that are found incidentally do not appear to be a danger to 
patients. It is quite possible that many patients are being wrongly treated.72  
 The controversy focuses on low-risk papillary carcinomas which constitute a 
significant portion of the increased diagnosis of thyroid cancer. There is evidence from 
studies by both Davies and Ito indicating that surgery might not be immediately 
necessary for some of these carcinomas and that at least some DTC patients accordingly 
could choose observation over immediate surgery. Davies conducted a retrospective 
study of 35,663 persons diagnosed with localized papillary carcinomas (any size but 
without metastases or extraglandular extension) between 1973 to 2005 which compared 
those who had surgery with the 440 patients (1.2%) who did not. The 20-year cancer 
specific survival rate (comparing those who died from papillary thyroid cancer) for the 
treated group was 99% as compared to 97% for those who did not receive immediate 
treatment.73 
 A similar study published at approximately the same time used the 1992-2002 
subset of the same database and compared mortality rates without the cancer-specific 
limitation of 7678 treated patients with the 47 who did not have surgery.74 The 
nonsurgically treated patients were older and had more advanced tumors. In this analysis, 
the one- and five-year survival rates for the surgically versus nonsurgically treated 
patients were 99% and 98% compared to 90.8% and 83.1%. The authors speculated that                                                         
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the survival differences may have been heavily influenced by co-morbidity (deaths from 
other illnesses) which is not described in the SEER database. Contrary to Davies, 
however, the authors still found these differences sufficient to prove the desirability of 
surgery. 
A study by Ito et al. tracked 732 papillary thyroid cancer patients. Patients with 
microcarcinomas (< 1 cm) without other risk factors were offered observation and 162 
chose to forgo surgery. Patients who developed various risk factors such as tumor growth 
or extension outside the thyroid received surgery subsequently while observation 
continued for the remainder. The authors found that 70% of the patients’ tumors either 
did not change in size or shrunk during an 8-year observation period and metastasis only 
occurred in 1.2% of cases indicating that surgical treatment was not necessary for most of 
the cases.75 A study by Moosa and Mazzaferri found that the much briefer delay in 
surgery until after birth had no adverse effects for pregnant women.76  
Ito et al. has continued to address the consequence of delaying surgery in low-risk 
patients. The follow-up study compared 1055 patients who had surgery with 340 who 
chose observation.77 Surgery was done if the tumor was adjacent to the trachea or 
laryngeal nerve, if there was nodal metastases or evidence that the tumor was aggressive. 
Observation was done by ultrasound 1-2 times per year and surgery was recommended if 
there was tumor enlargement greater than 3 mm (2 mm was believed to be possible 
observer variation), nodal metastases and when requested by the patient. There was                                                         
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enlargement after 10 years in 15.9%. Of the 340, 109 (31%) ultimately had surgery. This 
surgical group included patients who did not develop increased risk factors and excluded 
some who refused surgery despite developing risk factors. In comparing the two groups, 
there was no evidence that the delay in surgery had any adverse results. Ito’s studies have 
been widely cited. There does not appear to be any indication in the literature, however, 
that appropriate patients should be advised of these results when considering whether to 
have surgery. 
High-risk patients, particularly medullary and anaplastic, are less responsive to 
standard surgical and radiation treatment. Thyroidectomy has shown little benefit to these 
patients with metastatic thyroid cancer and doctors generally prescribe chemotherapy or 
radiation therapy with poor results.78 Stage III and IV patients are initially prescribed 
total thyroidectomy and administered higher concentrations of radioactive iodine post-
operatively.79 Like low-risk thyroid cancer treatment, high-risk treatment is accompanied 
by thyroid hormone suppression therapy to keep TSH levels low. Because TSH 
stimulates thyroid growth, high-risk patients have more aggressive TSH suppression. 
Radioactive iodine supplementation, serum thyroglobulin assays, and TSH suppression 
have shown efficacy in decreasing recurrence rates and cancer-related mortality in high-
risk patients though its efficacy in low-risk patients has not been established.80 External 
beam radiation (EBRT) is sometimes used as an adjunct to therapy but it has yet to be 
proven successful in curing patients. Patients require lifetime monitoring after therapy 
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because recurrence may occur years or decades later. Despite these efforts, anaplastic 
thyroid cancer in particular is essentially untreatable using currently available options. 
Studies analyzing the prevalence of thyroid cancer in patients containing cancer-
like nodules who are referred to surgery find approximately 45-55% malignancies in 
surgeries performed in teaching hospitals and highly specialized facilities.81  Much lower 
rates have also been reported. Stojadinovic et al., for example, reports 61% misdiagnosis 
on ultrasound and fine needle aspiration biopsy (FNAB) with 70-80% of surgeries 
finding no malignancy.82 While FNAB guided by ultrasound is both the most cost-
effective and accurate diagnostic tool with very high levels of accuracy when malignant 
or benign diagnoses are made, there remains a significant percentage of nodules found to 
be suspicious or indeterminate. The extent to which these nodules when biopsied after 
surgery turn out to be benign determines to a great degree the percentage of surgeries 
which then appear unnecessary. The high level of misdiagnosis apparently is caused by 
the lack of clear distinctions in nodule image between benign and malignant nodules. 
Also critical are the experience and competence of the cytologist and radiologist and the 
selection process employed by the referring physician.83   
It should be noted, however, that many of the imaging studies become suspect 
soon after publication because of the rate of change in imaging technology. The newest                                                         81 Lew, J. I., R. A. Snyder, Y.M. Sanchez and C.C. Solorzano, “Fine Needle Aspiration of the Thyroid: 
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technology, ultrasound elastography, which is based on the difference in stiffness in 
tumor walls compared to soft tissue, appears promising but has yet to be tested on a 
large-scale basis.84 The University of Miami and other institutions also have very 
recently implemented changes in the FNAB analysis classification system (the Bethesda 
system) which also are intended to reduce the number of unnecessary thyroidectomies.85 
 Epidemiological studies on thyroid cancer patients yield possible risk factors for 
thyroid cancer. Ionizing radiation exposure is the only established causative risk factor 
for thyroid cancer. Before the advent of antibiotics, radiation therapy was commonly used 
as a treatment for a variety of medical issues such as acne and enlarged tonsils, thymus, 
or lymph nodes in the neck. Between 1920 and 1960, when its effects became noticeable, 
over 100 million Americans were exposed to radiation therapy.  Exposure to nuclear 
energy fallout or too much low-dose radiation such as those found in X-rays and CT 
scans offers similar risk for thyroid cancer. 
As was previously discussed, after radiation, the most significant risk factor is 
benign thyroid disease and goiter particularly among women.86 There does not seem to be 
any literature that attempts to directly correlate the increase in thyroid disease with the 
increase in PMTC in women. There is some support for dietary (other than iodine-
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related) risk factors but again no significant studies that have related specific dietary 
changes to increased incidence of thyroid cancer.87   
Epidemiological studies on thyroid cancer yield some additional information on 
factors that are common across patients.  Family history of thyroid cancer is the most 
generic known risk factor. Approximately 5% of papillary thyroid cancer patients and 
25% of medullary thyroid cancer patients have a family member who has also been 
diagnosed with thyroid cancer.88 Age is another for more aggressive thyroid cancers with 
a poorer prognosis.  
Dietary iodine is a controversial risk factor for thyroid cancer. It is well 
established that iodine deficiency negatively affects thyroid function. Iodine’s association 
with thyroid cancer, however, is not clear. National Institute of Health research found that 
a diet deficient in iodine might increase the risk of follicular thyroid cancer. It also 
showed that over consumption of iodine increases a person’s risk for papillary thyroid 
cancer. Other research seems to show that iodine supplementation in iodine-deficient 
areas increases the incidence of DTC but lowers the incidence of anaplastic thyroid 
cancer with no overall change in mortality rates.89  Iodine supplementation is therefore 
worthy of consideration as a therapy for thyroid cancer prevention to the extent that 
papillary thyroid cancer becomes more treatable or perhaps should be provided to men to 
the extent research shows benefit due to their diminished vulnerability for papillary 
cancer.                                                            87 Chen, Amy Y. et al. “Increased Incidence of Differentiated Thyroid Cancer in the United States, 1988-
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Much of the current research on exposure to radioactive iodine has been 
associated with the nuclear energy industry because of radionuclides such as I-131 and I-
129 that are released after nuclear accidents. Chernobyl has been a particular focus of 
investigation.90 I-131 is filtered quickly through the body, but I-129 has a half-life of 16 
million years and concentrates in the thyroid where it is thought to cause cancer. More 
research is required to fully explore this issue. 
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Chapter 2: Growing Incidence and Prevalence of Thyroid Cancer 
Since 1973, the incidence of thyroid 
cancer has increased faster than any other 
endocrine malignancy and faster than any 
other cancer in women. The incidence has 
almost tripled in the United States since 1973 
according to the National Cancer Institute’s 
SEER data.91 Papillary thyroid cancer has 
comprised the largest proportion of the 
increase (see Figure 2). However, mortality 
remains stable despite the increased 
incidence.  
The prevailing theory explaining a 
substantial portion of the increase is the 
improved ability to diagnose due to 
advancements in detection technology 
particularly in ultrasound and fine needle 
biopsy. A landmark report in 2006 by Davies 
and Welch investigated the trends in thyroid 
cancer between 1973-2002 and concluded 
                                                        
 
91  I. Mitchell et al., "Trends in Thyroid Cancer Demographics and Surgical Therapy in the United States" 
Surgery (2007) 142:823-8; L. Davies and H. G. Welch, "Increasing Incidence of Thyroid Cancer in the 
United States, 1973-2002" JAMA (2006) 295:2164-2167. 
Figure 1: Age-Adjusted Incidence of Thyroid 
Cancer. Figure 2: Incidence of thyroid cancer by 
histology. Images and data derived from 
National Cancer Institute." SEER Fast Stats " 
Survelliance Epidemiology and End Results. 
http://seer.cancer.gov/faststats/selections.php?#O
utput (accessed 4/04/2012). 
32  
that the increased incidence rate should be attributed to “overdiagnosis.”92 The study 
found that 87% of the cases accounting for the increase were tumors smaller than 2 
centimeters, with 49% smaller than 1 centimeter. Additionally, the authors said there was 
no evidence to prove that therapy for cancers has improved such that it would account for 
the stability of mortality rate. Proponents of this theory also cite the increase in the 
number of cases referred to endocrinologists in which the patient’s thyroid tumor was 
found accidentally during imaging procedures taken for another reason.93 
Several studies subsequently concluded that the authors were partially mistaken. 
The increase did, in actuality, include some tumors of larger size and advanced stages, 
even those larger than 5 centimeters.94 A more recent study in Cancer that investigated 
trends in differentiated thyroid cancer between 1988-2005, for example, determined that 
increased detection could not be the only underlying cause for the increased incidence of 
larger cancers. The authors advocated for research to identify environmental, dietary, and 
genetic risk factors responsible for the increase.95 Although debate continues as to the 
extent of the real increase in incidence, it is clear that a significant part of the increase is 
only the diagnosis of what previously had been subclinical disease. 
As was previously discussed, therapeutic radiation treatments are a known risk 
factor. Its use on over 100 million Americans between 1920 and 1960 could account for                                                         
92 Ibid; Carmen Phillips, "NCI Cancer Bulletin Special Report: Thyroid Cancer's Rising Incidence: Reality 
Or Illusion?" National Cancer Institute, 
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some of the increase although the belief that radiation-induced thyroid cancer usually 
occurs within 5-20 years of exposure does not explain the continued increases after the 
1980’s.96  
Low-dose radiation remains an integral property of diagnostic imaging 
procedures. Procedures on children such as dental X-rays and increased use of CT scans 
in pediatric care could also account for some of the increase in cancer due to ionizing 
radiation. Children are known to be particularly vulnerable to thyroid cancer following 
radiation exposure.97 
There has also been an increase in the number of people near nuclear testing sites 
or nuclear accidents exposed to ionizing radiation, 
which may contribute to diagnosed cases. Belarus, 
Russia, and Ukraine are experiencing a significant 
increase in thyroid cases as a direct result of the 
Chernobyl nuclear accident. Studies in the United 
States of nuclear testing areas such as in Nevada, 
Tennessee, Ohio, Kentucky, Colorado, South 
Carolina, New Mexico, Idaho, New York, Texas, 
California, and Washington States also report not 
only an increase in thyroid cancer incidence but 
general autoimmune thyroid disease incidence as 
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well.98 
Recent evidence suggests that CT scans are the most dangerous current source of 
therapeutic radiation. Over 70 million people are diagnosed using CT scans per year, 
including thyroid cancer patients. CT scan use higher radiation doses than most imaging 
technology such as X-rays or MRIs and these doses are within a range that could increase 
cancer risk.99 In a National Cancer Institute Bulletin, Dr. David Brenner, of the Center of 
Radiological Research at Columbia said,  “Given the relatively short latency period for 
radiation-induced thyroid cancer…it is quite possible that CT is influencing current 
thyroid cancer rates in the United States in young people.” Current studies are looking 
into the risk.  
 There has also been an increase in exposure to toxic substances that are known to 
inhibit thyroid function but have yet to be associated with thyroid cancer. Perchlorate, a 
naturally occurring and manmade chemical used in rockets, missiles and other 
explosives, and fluoride are abundant in food and water supplies and are both known to 
interfere in iodine uptake in the thyroid. Polybrominated diphenyl ethers (PBDE) have 
also been linked to thyroid disorders. They are commonly used as a flame retardant in 
consumer goods in everything from clothing to electronics, including children’s products. 
Teflon, too has been found to affect thyroid function.100   Smoking is also a potential risk 
factor for thyroid problems, though it has not been explicitly linked to thyroid cancer. 
Cigarettes contain an anti-thyroid agent called thiocyanate.  Soy consumption is also a                                                         
98  McDougall, I. Ross. Thyroid Cancer in Clinical Practice (London Springer-Verlag, 2007) 3-10; Sara 
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100  Yu, X. M., Y. Wan, R. S. Sippel, and H. Chen. "Should all Papillary Thyroid Microcarcinomas be 
Aggressively Treated? An Analysis of 18,445 Cases" Annals of Surgery (2011) 254:653. 
35  
potential risk factor because soy has been shown to mimic the effects of estrogen in the 
body thereby triggering problems with hormonal regulation, a significant feature of the 
thyroid.  There is speculation that the increase may be due to wireless radiation in cell 
phones based on studies with rats.101 
            Some doctors are attributing increases in thyroid cancer and thyroid malignancies 
overall in the United States to iodine deficiency.  Iodine deficiency is not common in the 
United States since the addition of iodine into table salt. However, data from the National 
Health and Nutrition Examination Surveys (NHANES) since the 1970s showed that the 
rate of iodine deficiency in the United States has since quadrupled, directly correlating 
with the increased thyroid cancer rate data seen in National Cancer Institute surveys. The 
first NHANES survey showed only 2.6% of Americans between 1971-1973 demonstrated 
iodine deficiencies. Between 1988-1994 the figure increased to 11.7%. The study found a 
notable increase of iodine-deficient pregnant women (from 1% in 1974 to 7% in 1994), 
which is particularly alarming not only for the thyroid health of the baby but for mental 
health as well. It is possible that the recommendations for decreased salt intake for 
hypertension were responsible for the decreased intake.102  The ICCIDD speculates that 
decrease also may be attributed to an increased diet of processed and fast foods, which 
commonly do not use iodized salt.103 
Diagnosing iodine deficiency in patients can be difficult. Although bodily iodine 
can be easily measured through urine samples, a cut-off value for iodine deficiency has                                                         
101  Ibid. 102 International Council for the Control of Iodine Deficiency Disorders, "IDD Newsletter Nov 1999" 
International Council for Control of Iodine Deficiency Disorders, http://www.iccidd.org/media/IDD 
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never been established. Instead of diagnosing on the basis of each individual, iodine 
deficiency is diagnosed across populations as a median urinary iodine concentration less 
than 50 μg/L in the population of interest. Iodine deficiency is also generally treated as a 
public health measure across populations by adding iodine to common foods rather than 
treating individuals.104  The FDA, however, does not require the listing of iodine as an 
ingredient in food labels. 
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Chapter 3: Gender Distinctions in Thyroid Cancer 
       
It is well established that the incidence of thyroid cancer is significantly higher for 
females than males.105 Females account for about 75% of all thyroid patients. The 
incidence pattern is fairly consistent across all geographical and racial spheres.  The ratio 
between female to male incidence has remained almost constant with the increased 
overall incidence since 1973, with females higher than males. There is some evidence 
that female incidence may be even higher for papillary thyroid microcarcinoma. The 
National Cancer Institute’s Surveillance, Epidemiology and End Result (SEER) database 
for 1988 to 2007 contains 18,445 papillary thyroid microcarcinoma patients of which 
females were 82.7%.106 The largest follow up study in the literature showed a 8.9 to 1 
female/male ratio for Japanese patients.107  
The marked variation between male and female disease incidence has led to 
speculation on whether gender is a possible epidemiologic risk factor. The AMES risk 
categorization system discussed earlier explicitly relies on gender as a critical variable.108 
Further analysis has shown that the gender distinctions differ among types of thyroid 
cancer and the patient age. Differentiated thyroid cancer is about 3:1 female dominated, 
anaplastic thyroid carcinoma is 2:1 female dominated, and medullary (which does not 
develop from follicular cells like the other cancers) is equal incidence among genders.109 
Faratati et al. found that, at puberty, the female-to-male incidence ratio was as high as                                                         
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14:1 in DTC and then declines with age. Incidence rates in females peaks between 45-49, 
just before menopause when disease prognosis is also at its worst.110 The peak age for 
males is between 65-69.111 
Although females have an increased incidence of thyroid cancer, males 
demonstrate a poorer prognosis after diagnosis. The presence of large (greater than 5 cm) 
tumors doubles in males.112 Their tumors are also more likely to metastasize, both 
regionally and distally.113 Unsurprisingly, Mitchell et al. found that males were more 
likely to have advanced stage tumors at diagnosis. These factors, combined with the 
increased age at which men develop thyroid cancer, contribute to higher mortality rates 
among males (7.1%) compared to women (3.5%).114 
Not only is the mortality rate higher in males, but numerous studies have also 
provided evidence to show that gender is a significant independent predictor of mortality, 
even when stratified by age and stage of diagnosis.115 SEER data suggest males have a 
higher rate of reappearance of cancer after therapy even though females undergo less 
aggressive therapy.116    
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The reasons behind the discrepancy are poorly understood. The studies are 
inconsistent and controversial, but there are a number of prevailing theories. The four 
major theories proposed to account for the difference among genders in incidence levels 
are disproportionate screening, gender-specific behavior differences, variations in tumor 
biology, and biological sex differences. 
Because women are nine times more likely to develop non-cancerous thyroid 
conditions than men, doctors are more likely to prescribe surgical procedures or 
diagnostic imaging that would result in the discovery of a tumor.117 This also means that 
women have a greater tendency to be screened for thyroid conditions overall. In fact, the 
American College of Physician Guidelines include running blood tests to check for 
thyroid stimulating hormone levels for women over 50, while men rarely have their 
thyroid examined during routine medical visits. 
         Social behavioral differences among men and women in medical settings could 
also account for some of the difference in incidence. Women across all socioeconomic 
and racial groups are more likely to actively participate in their healthcare treatment then 
men. They utilize doctors and medical services to a greater extent and are more likely to 
engage with their doctors during visits, attend follow-up appointments, and listen to 
medical advice.  Doctors unconsciously have a tendency to order more tests for active 
patients. A side-result of this is that women are much more likely to undergo diagnostic 
testing (making it more likely for women to receive a diagnosis of cancer). This could 
partially account for why males are more likely to be diagnosed later in life.118 Although 
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these social and cultural hypotheses may have some degree of validity, it seems unlikely 
that they could account for all of the discrepancy. It is more probable that at least some of 
the discrepancy is founded on biological differences. 
Autopsy studies generally do not show any difference in male/female 
prevalence119 It has been postulated that the lack of male/female discrepancy in autopsy 
results is due to the difference in onset in which females have fast-growing nodules while 
males have slow-growing and eventually larger, and more easily visualized nodules.120 
This hypothesis has not been tested. 
An interesting alternative hypothesis also focuses on the many small, clinically 
irrelevant thyroid tumors that are only seen on autopsy studies, but never affect quality of 
life or mortality rates. Large autopsy studies demonstrate a high prevalence of incidental 
discovery of clinically unapparent tumors, especially in iodine-deficient areas with a high 
prevalence of nodular goiter.121  Some studies suggest that up to 50% of the population 
contain these tumors.122 Furthermore, it also seems that the determined frequencies in 
autopsies depend on the thickness and completeness of slices microscopically examined. 
The more closely the gland is studied, the more frequently such lesions are found. This 
has led some to suggest that the presence of these microcarcinomas may be “normal.” 
Since some of these microtumors, do become clinically significant, and do so at a 3 to 1 
female/male ratio, it is argued that there must be a biological basis for the transformation. 
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Some propose that normal thyroid tissue varies among sexes with female tissue 
more susceptible to the formation of tumors (tumorigenesis).123 Sex-specific hormones 
are known to play a role in disease, but there is little understanding of their role in normal 
thyroid function. A study used injections of estrogen and testosterone to show that the 
thyroid cell growth among female and male rats differed in association with sex-specific 
hormones.124 Further research is required to confirm this hypothesis. 
The most plausible theory for the cause of the gender distinctions, however, is the 
idea that female sex hormones, primarily estrogen, play a role in the pathology of thyroid 
cancer. As a result, estrogen has become a major target for new therapy research in 
thyroid cancer. Its primary evidentiary support is the decrease in incidence for females 
after menopause.  Elevated TSH levels are associated with increased thyroid cell 
growth.  TSH in women is known to elevate during parts of the menstrual cycle, during 
pregnancy, during treatment with hormone replacement therapy, and with birth 
control.125 As discussed in the introduction, mitochondria may be implicated in these 
biological pathways.   
There is no conclusive information on the link between estrogen and the 
development of thyroid cancer. Estrogen receptor status, however, has been shown to 
differ according to the type of thyroid cancer though estrogen receptor expression in cell 
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growth is not yet understood. As such, there is no definitive molecular element to explain 
the molecular basis of gender differences in thyroid cancer.126 
Studies on the influence of menopausal status have provided inconsistent 
evidence. The majority of studies have found that menopause does not have statistically 
significant correlation with thyroid cancer but that artificially induced menopause 
through surgery has an overwhelming association with thyroid cancer.127 Interestingly, 
women who had undergone only a partial oophorectomy (removal of ovaries), allowing 
some estrogen production had a decreased and nonsignificant risk for thyroid cancer. 
However, women who were given hormone replacement therapy following their surgery 
continued to show the same risk.128 Yao et al. hypothesize that the increased cancer risk 
in surgical menopause is due to the “sudden drop in estrogen levels with oophorectomy 
compared with the more drawn-out changes seen with natural menopause.”129 
Surprisingly, hormone replacement therapy, though found to deliver an increased risk in a 
number of different cancers, has no significant association with the development of 
thyroid cancer.130 
 Understanding the role of gender in thyroid cancer prevalence is important before 
any steps can be taken to treat it. Estrogen function seems to be the most promising 
theory. However, it is clear that our understanding remains limited and further research is 
necessary before we can be certain about the cause of the discrepancy. 
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Chapter 4: Thyroid Cancer as a Women’s Issue 
The ultimate cause for all cancers remains mysterious. As has been frequently 
noted, we do know that it is not caused by an insufficiency in surgical technique or a lack 
of sufficiently advanced pharmaceuticals. While limited progress has been made in 
curing cancer, public perception of cancer has changed dramatically in the last 50 years. 
There are now dedicated grants and institutions for the war on cancer and cancers that 
once held stigma for patients have become rallying points for people across the country, 
raising millions in funds for research and therapy. More importantly, changes in public 
perception have provided the impetus needed for public policy changes and awareness of 
the economic and political considerations necessary for successful approaches to 
treatment and medical advances in cancer.  
Thyroid cancer has not experienced the same level of public awareness and 
medical success that other cancers have seen.  This perhaps can be attributed to its 
relatively small incidence rate, comprising only 1% of all cancer incidence internationally 
and almost 2% in the United States. Attention is rarely given to diseases of low mortality 
that are not accompanied by a dramatically decreased quality of life. Thyroid cancer has 
neither a high mortality nor dramatically decreased quality of life and many who die do 
so fairly late in life. The median age of death from thyroid patients between 2005-2009 
was 73 years old.131 The prevailing belief that the increase was attributed to improved 
diagnostic capability rather than actual incidence also may have discouraged additional 
attention.  
                                                        131 National Cancer Institute, "Cancer of the Thyroid - SEER Stat Fact Sheets" 
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However, with the number of studies now demonstrating an actual increase, 
together with the massive increase in the number of patients, it is peculiar that thyroid 
cancer has not elicited more attention, if not for its prevalence among women, then 
simply because it is a type of cancer. The absolute numbers of people living with thyroid 
cancer is large enough for thyroid cancer to warrant becoming a political force. The 
National Cancer Institute’s SEER data state that “On January 1, 2009, in the United 
States there were approximately 496,901 men and women alive who had a history of 
cancer of the thyroid -- 108,920 men and 387,981 women.”132 
The struggle for visibility in thyroid cancer is reflected in its failure to become a 
women’s issue despite its existence as a growing problem for young women. 
Approximately 10% of the DTC cases affecting women during their reproductive years, 
occur during pregnancy or within a year of childbirth.133 Although twice as many women 
are diagnosed with thyroid cancer as ovarian cancer each year in the United States, it has 
yet to be classified as a woman’s cancer by the National Cancer Institute.134 
Because of the lack of awareness and distinguishable symptoms, doctors often 
overlook signs that indicate a thyroid cancer diagnosis. Most symptoms resemble “female” 
problems associated with menstruation and menopause. These include fatigue, nausea, 
skin and hair hypopigmentation, and general discomfort. These symptoms frequently are 
disregarded as feelings rather than concrete indicators like fever. 
Women do not even realize what a diagnosis of thyroid cancer entails. In an 
article entitled, “Dear Thyroid, Thanks for Nothing, You Jerk,” Megan Johnson writes:                                                         132 Ibid. 
133  Haq, Masud S. and Clive Harmer, “Non-surgical Management of Thyroid Cancer” in Practical 
Management of Thyroid Cancer: A Multidisciplinary Approach 175. 
134  National Cancer Institute, Cancer of the Thyroid - SEER Stat Fact Sheets.  
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I couldn’t even get the cancer other women get.  No, my disease doesn’t come in 
pink, isn’t globally recognizable and supported, doesn’t have multiple multi-
million-dollar fundraising organizations attached to it – even the treatments are 
different.  Every time someone learns I have cancer, I have to explain how I 
didn’t have chemo, how my hair didn’t fall out, and how I even GAINED 
weight.  No one understands why, now that it’s “gone,” I still can’t stay up late or 
get fewer than 8-9 hours of sleep without feeling ill.135   
Johnson, along with countless other thyroid cancer patients, recounts years of struggle 
through the medical establishment with diagnoses of depression, unexplained weight gain, 
or goiter, before their doctors arrive at the accurate diagnosis. 
Breast cancer, in contrast, has gained momentous attention over the past two 
decades. Prior to the 1980s, breast cancer was a stigmatized subject, rarely mentioned in 
public. In the late 1970s, Betty Ford came out as the symbol of breast cancer, advocating 
its awareness for the first time. More recently, pink ribbons have become synonymous 
with the campaign for breast cancer awareness. There are countless walks and 
fundraising events to support breast cancer patients and research. There is no doubt that 
the publicity has paid off financially: in 2010, the National Cancer Institute spent $631.6 
million on breast cancer, 40 times more than that spent on thyroid cancer. Recently, 
breast cancer became one of the few cancers with a decreasing incidence rate.  
Despite the difference in societal perception, the two cancers share similar 
biological features. Studies have found an increased risk of thyroid cancer in individuals 
with a history of breast cancer and an increased risk of breast cancer in those individuals 
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with a history of thyroid cancer.136 There is increasing concern that the 131I treatment for 
thyroid cancer is a risk factor for breast cancer.137 Some, however, believe that breast 
cancer and thyroid cancer are simply both primarily found in women, that someone who 
suffers from one form of cancer is more susceptible to other cancers or that women are 
generally more susceptible to cancer and that no causative factor exists between the 
two.138 Both thyroid and breast cancer have been associated with sex steroid receptor 
mutations and the presence of estrogen receptor and progesterone receptor expression can 
affect disease prognosis and treatment options. These similarities could provide the link 
needed to generate a new level of awareness.  
Thyroid cancer has failed to produce any advocates or anything concrete for 
which to advocate. Whereas breast cancer patient advocate groups could fight for 
insurance coverage of mammograms, thyroid cancer has no rallying point. There is 
nothing to demonstrate cost-effectiveness of screening for thyroid cancer.  No 
preventative measures have been established to date.139 As a result, thyroid cancer 
patients do not have a platform to promote thyroid health. Whereas doctors can annually 
screen for cervical cancer via pap smear, DTC thyroid cancer has no similarly useful 
diagnostic tool. There is nothing that is known to prevent thyroid cancer.  If thyroid 
cancer treatment could achieve the same level of urgency as breast cancer, research might 
identify measures needed for its prevention. 
                                                        136 McDougall, I. Ross. Thyroid Cancer in Clinical Practice. London Springer-Verlag, 
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Current thyroid cancer treatment has some obvious corollaries with the early 
treatment of breast cancer. The late 1880s saw the development of initial surgeries for 
breast cancer and the discovery that post-operative cancer recurrence could be attributed 
to parts of the original tumor that metastases and escaped the knife. In response, Halstead 
developed his radical mastectomy, cutting out not only breast tissue, but also the 
pectoralis minor and through the pectoralis major, the muscle responsible for significant 
movement in the shoulder and hand. As Siddhartha Mukherjee relates in his biography of 
cancer, “even more breast tissue was removed during the initial operation. Since the 
margins of extirpation were the problem, then why not extend the margins?”140 When 
that failed to cure cancer, surgeons would excavate even deeper into the chest, through 
the collarbone, and strip out the lymph nodes underneath.141 
The procedure remained the height of surgery for almost 50 years, forcing women 
to undergo indiscriminate, disfiguring and gruesome operations without any benefit. Its 
allure and glamour inspired surgeons across all cancers and increasingly radical surgeries 
were performed each day. By 1929, an English surgeon wrote “the measure of operability 
depend[ed] on the question: ‘Is the lesion removable?’ and not on the question: ‘Is the 
removal of the lesion going to cure to patient?’”142 
The treatment of thyroid cancer appears to follow the same thought process. In the 
case of thyroid cancer, the primary lesion is always removable through thyroidectomy. 
Haymart hypothesizes that increased detection of low-risk disease can lead to 
overestimation of treatment efficacy and a subsequent increase in use of therapy and it                                                         
140  Siddhartha Mukherjee, The Emperor of all Maladies: A Biography of Cancer (New York Scribner 
2010). 
141  Ibid. 
142  Ibid. 
48  
certainly makes sense to remove a malignancy prior to metastasis. The problem is that 
there may already have been metastasis or it may have been a malignancy that would 
never have become clinically significant. The continuing difficulty is the lack of change 
in mortality rates. If 50% of the increased incidence is simply the result of improved 
diagnosis, what is the basis for believing that its treatment is beneficial to the patient? 
The history of the radical mastectomy has showed the importance of research to 
determine what is clinically significant and this research remains lacking in thyroid 
cancer. As the main beneficiaries of thyroid cancer awareness and treatment, it is 
important for women to come forward to advocate for thyroid cancer research to ensure 
that history does not continue to repeat itself. Thyroid cancer results in a significant and 
increasing amount of surgery on women. Furthermore, female thyroid cancer 
disproportionally accounts for the large number of the cases of small tumors which 
appear to be clinically irrelevant.   The ethical issues relating to treating huge numbers of 
patients simply because it will benefit an unidentifiable much smaller number of patients 
deserves considerably more attention than it has received in the literature. 
Although the literature does not seem to suggest that women are being treated 
disproportionately due to gender bias, gender bias must be considered due to its high 
prevalence in the American health care system. Traditionally, research on diseases 
specific to females receives low priority unless directly related to reproduction.143 More 
emphasis needs to be placed on generating female interest groups in thyroid cancer to 
advocate for more research to determine appropriate treatment for hundreds of thousands 
of women.                                                         
143  L. Baider and J. Bengel, "Cancer and the Spouse: Gender-Related Differences in Dealing with Health 
Care and Illness" Critical Reviews in oncology/hematology (2001) 40:115. 
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Chapter 5: Implications for Health Policy 
 
Thyroid cancer and particularly differentiated thyroid cancer present public policy 
challenges on several levels. There are the medical/public health problems of identifying 
the most appropriate care and addressing the burdens of hundreds of thousands of 
patients who do not have functioning thyroids. Because medical certainty is not likely in 
the near future, there also are ethical issues concerning how best to communicate choices 
to low-risk patients that respect patient autonomy. Finally, there are the economic issues 
presented by the costs of treatment.  
As the fastest growing cancer and an illness that affects the lives of hundreds of 
thousands each year, the impact of these challenges will be magnified in the next decade. 
A significant part of this impact will be the result of medical decisions based on 
incomplete data. The 2009 Guidelines, for example, recommend surgery for any 
malignant nodules larger than 1 centimeter. This fairly arbitrary cut off, if followed, 
creates a population of patients. A decision to remove smaller nodules expands the pool 
of patients. Many malignant modules have no clinical significance as measured by 
mortality. This is shown by the lack of mortality change despite enormous increases in 
the number of patients treated. Treatment decisions therefore are being made which 
presumably benefits some subset of patients at the cost of unnecessary treatment to others. 
  It is possible to begin to imagine the scale of this issue. It is estimated that 10-18 
million adults in America have a palpable thyroid nodule, 95% of which are 
benign.144  Studies have found that anywhere from 2-60% of the population have small 
benign thyroid nodules and it appears that many of these will be diagnosed as                                                         
144  A. B. Mariotto et al., "Projections of the Cost of Cancer Care in the United States: 2010-2020” 
National Cancer Institute (2011) 103:117-128. 
50  
cancer.145 The potential impact of these kinds of numbers is illuminated by Sarlis and 
Gourgiotis’ summary based on other estimates of the magnitude of malignant thyroid 
cancer nodules in the United States: 
From the above data, it appears that clinically occult TC [thyroid cancer] has 
minimal clinical importance. The very same data pose the dilemma of optimal 
management of incidentally discovered thyroid nodules, given the fact that the 
size threshold—among experienced examiners—for palpation of thyroid nodules 
is 1.0-1.5 cm. Most experts advocate fine needle aspiration biopsy (FNAB) of all 
thyroid nodules larger than 1.0 cm. By applying the above criterion and assuming 
that ~40-50% of the population harbors inapparent thyroid nodules, as well as that 
~30% of these nodules will be greater than 1.0 cm in size, one would then 
conclude that ~10-12% of the population could be candidates for a diagnostic 
FNAB. Theoretically, if all the above individuals were biopsied, and with an 
estimated 5% malignancy rate, up to 0.6%-0.7% of the general population could 
end up with a diagnosis of TC! This rationale could well create a public health 
conundrum, considering that the majority (>80%) of the TCs diagnosed in this 
manner would never become clinically significant during an individual's 
lifetime.146 
 
The impact of current treatment practices is also apparent upon consideration of 
Yu et al.’s summary of the papillary thyroid microcarcinoma patient files in the SEER 
database for 1988-2007.147 The 18,445 patients had 10-year and 15-year disease specific 
survival rates of 99.5 and 99.3 respectively with an overall survival of 94.6 and 90.7. 
There were 49 deaths from thyroid cancer. If we accept Davies’ estimate of a 2% increase 
in survival from surgery, there are thousands of surgeries required to prevent 1 death. If 
we accept Ito’s finding that 70% of the low risk patients do not require surgery, the 
conclusion is similar. Davies’ estimate of surgical advantage could be increased by an 
                                                        
145  L. Davies and H. G. Welch, "Increasing Incidence of Thyroid Cancer in the United States, 1973-2002" 
JAMA (2006) 295:2164-2167; Y. Yamamoto et al., "Occult Papillary Carcinoma of the Thyroid. A Study 
of 408 Autopsy Cases" Cancer (1990) 65:1173-1179. 
146  N. J. Sarlis and L. Gourgiotis, "Unresolved Issues, Dilemmas and Points of Interest in Thyroid Cancer: 
A Current Perspective" Hormones (2004) 3:149-170. 147 Yu et al, “Should All Papillary Microcarcinomas be Aggressively Treated?” Annals of 
Surgery (2011) 254:653.  
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order of magnitude without a substantial change in the issues raised by current treatment 
practices. Ito is not even challenging current treatment practices but simply suggesting 
observation as an initial stage for a subset of patients who have been repeatedly shown to 
have little risk. This attempt to quantify the many thyroid cancer patients who gain 
limited or no benefit from surgery also does not include those who go through surgery 
and have negative findings for cancer when the thyroid is examined. 
It seems evident that more focus on avoiding unnecessary surgery is required. 
Recognizing that some papillary cancer patients have potentially aggressive disease 
which requires treatment, is not grounds for treating patients who do not meet this profile. 
In reviewing the literature, part of the problem appears to be the use of diagnostic labels 
that blur the issues. Discussion of “thyroid cancer,” for example, is virtually meaningless 
in many contexts. The different histological variants are simply different diseases with 
different diagnoses and prognoses. While reference to the subset of DTC is an 
improvement, there still is too much variation for clinical utility. Given the generally 
benign outcome of PTC, a long-term study which includes tall cell or columnar papillary 
cancer within a broader group of PTC patients may change the results in a statistically 
significant manner. Similarly, assuming for example the reliability of data showing that 
there is a 2.7 per 100,000 mortality rate for persons >age 65 compared to .1 <age 65, a 27 
times difference, studies need to take care to separate out these patient populations based 
on the various identified risk factors.148  
                                                        148 Yu et al, “Should All Papillary Microcarcinomas be Aggressively Treated?” Annals of 
Surgery (2011) 254:657.  
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Another somewhat similar issue is the continued use of older studies to justify 
overtreatment and to continue past practices. There have been significant advances in 
measuring tumor size and in the ability to visualize and monitor nodules technologically 
and significant expansion in clinical experience resulting from the dramatically increased 
patient volumes, which make many studies obsolete. It is not particularly clear, for 
example, why the current practice of measuring a tumor by its longest diameter is more 
meaningful than measuring volume. Recent developments in genetics are resulting in new 
subsets of patients whose clinical experience may vary from broader less specific patient 
cohorts. If we are going to assume that any substantial portion of the increased incidence 
is real, the assumption that a prospective study is too expensive will probably not survive 
the changed economics created by hundreds of thousands of thyroid cancer and 
thyroidectomy patients. 
 The need to start focusing on eliminating unnecessary care also is based on 
economics. The American health care system is exorbitantly expensive. In 2007, 
Americans spent more than $2.3 trillion and more than 16% of GDP on health care.149 In 
2005 the cost was $5,267 per capita on health care per year, almost two and half times the 
industrialized world’s median of $2,193.150 Both figures are more than those of any other 
developed country in the world. Current projections anticipate increases to almost $4.5 
trillion and a 19.3% share of GNP by the end of the decade.151  The cost of health care 
                                                        
149  Drew Altman, “Health Reform, What's Next?” (2010). 
150  Malcolm Gladwell, "The Moral-Hazard Myth," New Yorker (08/29, 2005) 81:44-49. 
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increases about 12.5% annually, contributing substantially to the growing number of 
Americans without health insurance.152   
 Quantifying the financial burden of 
cancer specifically is difficult. 
Conservative estimates for medical 
expenditures for cancer in 2010 are $124.6 
billion. The highest costs are associated 
with breast cancer ($16.5 billion), then 
colorectal cancer ($14 billion), lymphoma 
($12 billion), lung cancer ($12 billion) and 
prostate cancer ($12 billion). The costs are 
projected to reach $158 billion in 2010 
dollars by 2020, assuming that cancer 
incidence and survival rates and costs remain the same.153 The rising cost of innovative 
procedures in cancer diagnosis, pharmaceuticals and other treatment, and follow-up care 
makes these assumptions unrealistic, however, and a more accurate projection, according 
to the National Cancer Institute would be at least $207 billion. Future health care 
resource allocation will therefore need to become more focused and efficient to remain 
affordable. 
                                                        
152  Ceci Connolly, "Medicine; A Few Diseases Fuel Healthcare's Rising Cost; Citing 15 Major Illnesses, a 
Study Says Proactive, Affordable Treatments can Help Stem the Tide." Los Angeles Times Sep 6, 2004, 
http://proquest.umi.com/pqdweb?did=688481411&Fmt=7&clientId=42799&RQT=309&VName=PQD. 
153  National Cancer Institute, "Cancer Costs Projected to Reach at Least $158 Billion in 2020," 
http://www.cancer.gov/newscenter/pressreleases/2011/CostCancer2020 (accessed 4/18/2012); Mariotto et 
al., Projections of the Cost of Cancer Care in the United States: 2010-2020, National Cancer Institute 
(2011) 103:117-128. 
 Figure 1: Cost of Cancer in 2010 as determined by the National Cancer Institute. Cost is divided into 3 
categories: Initial Treatment, Continuing Care, and 
End of Life (Last) Care. Image generated from 
National Cancer Institute. "SEER Fast Stats" 
Survelliance Epidemiology and End Results. 
http://seer.cancer.gov/faststats/selections.php?#Outpu
t (accessed 4/22/2012, 2012). 
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 The total cost associated with treating thyroid cancer is even more difficult to 
determine. There does not appear to be any published data regarding total costs of non-
metastatic thyroid cancer or management of long-term care for thyroid cancer.154 There 
also does not appear to be any published data on the costs of treating patients for potential 
thyroid cancer. Some idea of the scale of this latter issue is shown by estimates that there 
will be approximately 250,000-300,000 thyroid fine needle aspiration biopsies in 2012 of 
which an estimated 70% will be benign.155 There has been some limited research 
demonstrating the unsurprising conclusion that avoiding unnecessary radioactive iodine 
treatment would achieve cost savings and it is obvious that avoiding unnecessary 
treatment itself would yield enormous cost savings.156   The National Cancer Institute estimates health care costs associated with total 
neck and head cancer will amount to approximately $3.5 billion in 2012 (figure 1). Two 
of the assumptions on which this estimate is based, that incidence will remain constant 
based on 2003-05 average rate and that costs will not increase, appear to be mistaken.  
Some perspective on the actual scale of increase in thyroid cancer alone is shown by the 
estimated 18,400 cases diagnosed in 2000, the 25,700 in 2005, 37,000 in 2009 and the 
estimated 56,000 in 2012. As discussed below, the 2012 costs of metastatic thyroid 
cancer alone may exceed $3.5 billion. Thyroid cancer represents the overwhelming 
percentage of head and neck cancers and it accordingly may be assumed that current 
costs substantially exceed the $3.5 billion estimate.                                                          
154  Rebecca L. Brown, "Thyroid Cancer: Burden of Illness and Management of Disease" Cancer (2011) 
2:193. 
155  S. Luo et al., "Screening of Thyroid Nodules by Ultrasound Elastography using Diastolic Strain 
Variation " Conference Proceedings: Annual International Conference of the IEEE Engineering in 
Medicine and Biology Society. Conference 1 (2009): 4420-4423. 
156  P. Z. Pace-Asciak et al., "Cost Savings of Patients with a MACIS Score Lower than 6 when 
Radioactive Iodine is Not Given" Archives of Otolaryngology--Head & Neck Surgery 133 (2007): 870-873. 
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 Metastatic thyroid cancer expenditures have received some attention in 
policymaking among thyroid cancer cases perhaps due to the much higher death rates. 
Studies indicate that 1-4% of DTC patients will present with metastatic cancer and 
another 5-23% will have a reoccurrence of metastatic cancer after surgery with survival 
rates below 50% after 10 years. A study using a US health insurance database, which 
covered over 14 million lives, determined the per patient costs of metastatic thyroid 
cancer between 2003 and 2005 to be $60,196 during the first year and $35,189 during the 
second year of follow-up. The retrospective longitudinal cohort study followed 183 
patients with newly metastatic thyroid cancer.157 Inpatient care was the main driver of the 
total healthcare expenditure, and represented 43% of all costs. Radiation therapy was 
used in 23%, 131I therapy in 19%, thyroid surgery in 13%, and chemotherapy in 11% of 
patients.  
There were 2823 people diagnosed with metastatic thyroid cancer in 2011.158 If 
there were no increases in costs from the 2003-05 figures and no increase in patients from 
2011, this represents a $2.8 billion expense assuming approximately similar numbers 
were in follow-up care. If the 12.5% estimated average annual increase in health care 
costs is applicable here, then actual costs after the seven years from 2005 will be more 
than double the estimate.159   
It also seems likely that this study significantly understates current costs. For 
example, it did not consider the extremely high costs of newer targeted agents, drugs                                                         
157  A. Berger et al., "Healthcare (HC) Utilization and Costs in Patients (Pts) with Newly Diagnosed 
Metastatic Thyroid Cancer (mTC)." Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 25, 
no. 18S (2007) (accessed 4/21/2012). 
158  National Cancer Institute, "Cancer of the Thyroid - SEER Stat Fact Sheets" 
http://seer.cancer.gov/statfacts/html/thyro.html (accessed 4/21/2012). 
159  Connolly, Medicine; A Few Diseases Fuel Healthcare's Rising Cost; Citing 15 Major Illnesses, a Study 
Says Proactive, Affordable Treatments can Help Stem the Tide F.3.   
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expressly designed to address specific pathways in differentiated thyroid cancer. The 
National Institute for Health and Clinical Excellence (NICE) in Great Britain has 
considered this issue for the same drugs in relation to other types of cancer. NICE, which 
is required to determine the cost effectiveness of new medications in comparison to the 
older treatment, has determined as to several targeted agents that they are not cost 
effective. Unless the relevant pharmaceutical company chooses to dramatically decrease 
drug costs, it seems likely that similar determinations will be made as to their use in 
thyroid cancer.160  
It is also apparent that the decision whether to invest public health resources in 
thyroid cancer care will have to be made using very limited information. Biersack and 
Grunwald, for example, state that in the United States only about 60% of diagnosed 
thyroid cancer cases are reported to the National Cancer Institute.161 More 
importantly, because overall prognosis for DTC is so good, the epidemiological research 
necessary to make diagnostic and therapeutic decisions requires analyses of very large 
cohorts over extended periods of time.162  The lengthy amount of time between disease 
onset and symptoms with subsequent limited mortality makes it hard to detect beneficial 
practices or who would have done well regardless of treatment.  Over the course of 
lengthy studies, it also is likely that there will be significant changes in treatment and 
there may be changes in environmental, cultural or other factors that themselves will have 
an impact on interpretation of results.  The studies then will fail to provide information on 
the current protocol, and will likely fail to accurately determine causation resulting from                                                         
160  Brown, “Thyroid Cancer: Burden of Illness and Management of Disease” Cancer (2011) 2:197-198. 
161 Gorges R., “The Changing Epidemiology of Thyroid Cancer” in Thyroid Cancer: Current Concepts in 
Diagnosis and Therapy ed Biersack, H.J. and Grunwald, F. (2005) 1. 
162 Ibid. at 2. Villaret and Mazzaferri in Mazzaferri, Practical Management 135. 
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the impact from changes in technology.  Considerations like national representativeness 
of the population sample, method of diagnosis, and determination of the long-term 
survival rates will further complicate the reliability of epidemiological studies.163  
 The screening conundrum in thyroid cancer has some obvious parallels with the 
current controversy with mammography policy in breast cancer and PSA testing policy in 
prostate cancer. Both have been used in the general population despite a lack of 
conclusive clinical-trial evidence that they save lives, and as the tests are becoming more 
available there is concern that they themselves are causing damage. Studies estimate that 
about half of men and women who are screened annually will receive a false-positive. In 
a study in Detroit of 1,087 people who were tested for prostate, ovarian, colorectal and 
lung cancer, 43% had false-positives for cancer.  
There is a significant financial and emotional toll on the cancer patients and their 
families for cancer diagnosis as well as false-positives. According to the Wall Street 
Journal:  
“The assumption has been that as long as a person eventually find out that 
first test was wrong [or does not indicate certain death], any distress is transitory 
and minor – and that the cost of additional testing is worthwhile for the peace of 
mind it brings. Instead, several studies reveal that the impact of false positives can 
be serious and persist far longer than expected…A study in the American Journal 
of Medicine found that a significant proportion of men who had an elevated PSA 
test [for prostate cancer] followed by a benign biopsy result still felt negative 
psychological effects from the experience six weeks later…And the medical costs 
of unnecessary additional testing can be considerable. In a study published [in 
2004] researchers found that men and women who had false-positive screening                                                         
163 Gary Taubes, "Do We Really Know What Makes Us Healthy?" New York Times Magazine (09/16, 
2007): 52, http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=28697580&site=ehost-live. 
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results averaged more than $1,000 each in follow-up care in the year following 
the test.”164 
The same study found that 25% of the men who were in the group that had a benign 
biopsy said that they had additional biopsies because their doctors wanted to make sure 
that the first one truly was benign.165  
 However, while in mammography and PSA testing the major issue is the financial 
and emotional expense of screening disease with significant mortality but uncertain 
benefit, in thyroid cancer, the major issue is that there are so many people who present 
with nodules known to be clinically insignificant that it is uncertain whether any 
treatment is appropriate. As was discussed above, there are significant side effects to 
thyroidectomies and radioactive iodine treatment. If increased screening results in 
increased treatment, there will be a small portion of patients who may benefit, but there 
appears to be an even larger portion who, in addition to being screened for no reason, 
may be being harmed for no reason. 
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Conclusion 
The issues discussed in the previous chapters demonstrate the limits of our current 
knowledge in thyroid cancer. We have yet to understand the factors that influence cancer 
outcomes, especially in thyroid cancer, and have difficulty evaluating, much less 
implementing the best outcome for each thyroid cancer patient. The diagnosis and 
incidence of thyroid cancer is increasing at such an alarming rate as to warrant increased 
research. The National Cancer Institute’s SEER data shows that there were approximately 
500,000 living Americans who had a history of thyroid cancer in 2009.166 This 0.5 
million patient population will increase dramatically without changes in our current 
approach to thyroid cancer issues. Thorough investigation is needed to stop treatment of 
those cancers that lack clinical significance. 
Patient education is a neglected aspect of thyroid treatment. Public awareness in 
thyroid cancer is limited. It is common knowledge that too much sun exposure may cause 
skin cancer and smoking dramatically increases the risk of lung cancer. Relatively few 
people in the general population, however, know anything about risk factors for thyroid 
cancer or even the location of the thyroid in their body.  
It also is quite possible that the increase in papillary thyroid cancer, and the 
corresponding increase in overall thyroid disease that is not due to improved technology, 
is an indication of some environmental contamination. Instead of disregarding thyroid 
cancer because of its low mortality, the medical community should consider the 
possibility that it is a canary in a public health mine. Women in particular need to 
demand greater attention of this issue.                                                         
166 National Cancer Institute, Cancer of the Thyroid - SEER Stat Fact Sheets.  
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